Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects

Matthew W. McClure,Elina Berliba,Tengiz Tsertsvadze,Adrian Streinu Cercel,Leen Vijgen,Béatrice Astruc,Alain Patat,Christopher Westland,Sushmita Chanda,Qingling Zhang,Thomas N. Kakuda,Jennifer Vuong,Nick Khorlin,Leonid Beigelman,Lawrence M. Blatt,John Fry

Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects

2018

Matthew W. McClure
Elina Berliba
Tengiz Tsertsvadze
Adrian Streinu Cercel
Leen Vijgen
Béatrice Astruc
Alain Patat
Christopher Westland
Sushmita Chanda
Qingling Zhang
Thomas N. Kakuda
Jennifer Vuong
Nick Khorlin
Leonid Beigelman
Lawrence M. Blatt
John Fry

Background The nucleotide analog AL-335 is a pangenotypic hepatitis C virus (HCV) nonstructural protein (NS)5B inhibitor being evaluated as treatment for chronic HCV infection.

Keywords:

Hepatitis C virus
Virology
Medicine
Tolerability
Pharmacokinetics
safety tolerability
healthy volunteers
Gastroenterology
Internal medicine
Placebo
Drug
Cirrhosis
Genotype

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations